Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Rebating Bills In House, Senate Come Into Alignment As Passage Likely Punted to 2024

Executive Summary

Legislation to delink PBM payments from drug prices advances in House Energy and Commerce health subcommittee, putting a key pharma priority closer to the finish line. Whether patients will see any benefit remains a worry.

You may also be interested in...



Strong House Vote On PBM, Generics Bill Sets Stage For Early 2024 Action

Easy House passage of a health package that includes PBM reforms and policies to help generic drug makers likely creates enough momentum to spur bicameral action. Overall policy still a work in progress – presenting last-minute opportunities for other drug pricing reforms to get tacked on.

Strong House Vote On PBM, Generics Bill Sets Stage For Early 2024 Action

Easy House passage of a health package that includes PBM reforms and policies to help generic drug makers likely creates enough momentum to spur bicameral action. Overall policy still a work in progress – presenting last-minute opportunities for other drug pricing reforms to get tacked on.

Medicare Incentives For Quality Drugs Should Not Wait For US FDA Ratings, Experts Tell Congress

Medicare payment for higher quality drugs would help abate shortages, experts with the Brookings Institution, Civica Rx and University of California say. Brookings’ Wosińska explains how hospitals could identify quality generic injectable drug manufacturers without waiting for FDA quality ratings.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel